Literature DB >> 12489242

Ophthaproblem. Ocular myasthenia gravis.

Stephanie Baxter1, Sanjay Sharma.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12489242      PMCID： PMC2213959     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  8 in total

1.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

2.  The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK.

Authors:  B K MacDonald; O C Cockerell; J W Sander; S D Shorvon
Journal:  Brain       Date:  2000-04       Impact factor: 13.501

3.  Indications for thymectomy in myasthenia gravis.

Authors:  D J Lanska
Journal:  Neurology       Date:  1990-12       Impact factor: 9.910

4.  Beneficial effects of corticosteroids on ocular myasthenia gravis.

Authors:  M J Kupersmith; M Moster; S Bhuiyan; F Warren; H Weinberg
Journal:  Arch Neurol       Date:  1996-08

5.  Ocular Myasthenia Gravis.

Authors:  Victoria S. Pelak; Steven L. Galetta
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

6.  Single fiber electromyography of extraocular muscles: a sensitive method for the diagnosis of ocular myasthenia gravis.

Authors:  A Rivero; L Crovetto; L Lopez; R Maselli; M Nogués
Journal:  Muscle Nerve       Date:  1995-09       Impact factor: 3.217

7.  Myasthenia gravis: antibodies to acetylcholine receptor in ocular myasthenia gravis.

Authors:  K Oda; Y Ito
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

8.  Prognosis of ocular myasthenia.

Authors:  C T Bever; A V Aquino; A S Penn; R E Lovelace; L P Rowland
Journal:  Ann Neurol       Date:  1983-11       Impact factor: 10.422
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.